Addition of GLP-1 Therapy to Insulin in C-Peptide-Positive Patients with Type 1 Diabetes

We have previously demonstrated that the addition of liraglutide to insulin significantly improves the glycemic control in patients with type 1 diabetes (T1D) with undetectable c-peptide. We have now investigated whether the addition of GLP-1 therapy to insulin in c-peptide positive patients with T1D will increase the c-peptide concentrations and improve the glycemia further with reduced insulin requirements. We conducted a retrospective analysis of 11 Caucasian patients with detectable c-peptide and positive GAD-65 antibodies treated with GLP-1 therapy for 12±1 weeks (baseline c-peptide: 0.43±0.09 ng/ml; baseline HbA1c: 10.63±0.87%; mean age: 43±5 years; mean age of diabetes diagnosis: 37±5 years; mean duration of diabetes: 6±2 years; mean BMI: 23± 1Kg/m 2 ; mean body weight: 71±2 kg; 6 females, 5 males). At the end of 12± 1 weeks of GLP-1 therapy; c-peptide concentrations increased significantly from 0.43±0.09 to 1.42±0.42ng/ml(p=0.01); HbA1c fell from 10.63± 0.87% to 7.45± 0.52%(p Disclosure N.D. Kuhadiya: Speaker9s Bureau; Self; AstraZeneca, Novo Nordisk A/S, Janssen Scientific Affairs, LLC.. Advisory Panel; Self; AstraZeneca. Consultant; Self; Dexcom, Inc.. B. Prohaska: None. H. Ghanim: None. P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca.